Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA says Alliance Pharma's Imavist "approvable":

This article was originally published in Clinica

Executive Summary

Alliance Pharmaceutical's cardiac ultrasound imaging agent Imavist has moved a step closer to US market, after the FDA decided that the agent was "approvable". Final product approval is dependent upon Alliance's submission of additional information related primarily to product labelling. The San Diego, California firm, which is developing the agent jointly with German firm Schering, said it expected to respond to the FDA within the next few weeks. The information that will be supplied to the agency includes patient subgroup analyses, a recently completed pharmacokinetic report and an updated plan for post-approval product release testing.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel